Antibodies and proteins for the analysis of tumor suppressors

Tumor Suppressors

Antibodies for the characterization
of tumor suppressor proteins

Mutations in tumor suppressor genes, such as TP53, and oncogenes such as H-Ras account for the development for a large variety of cancers.

Mutations in tumor suppressor genes, such as TP53, and oncogenes such as H-Ras account for the development of a large variety of cancers.

Mutations in two gene groups, tumor suppressors and oncogenes, play an important role in inducing and promoting a large variety of cancers. Oncogenes tend to encode growth factors, growth factor receptors, cell signaling proteins and transcription factors, while tumor suppressor genes encode cell cycle regulators. Most oncogenes are activated via point mutations, gene amplifications and gene translocations in a normal gene known as proto-oncogene and result in altered gene expression or protein activity levels (Lodish et al. 2000). In contrast to oncogenes, mutant tumor suppressor genes are recessive. They follow the Knudson or “multiple-hit hypothesis”, which suggest that both alleles of a gene need to be mutated in order to trigger disease onset.

In spite of this hypothesis, the inheritance of certain mutant tumor suppressor alleles, such as BRCA1 and BRCA2 mutant alleles, significantly increase the risk of developing breast and ovarian cancers. For example a female carrying a mutant BRCA1 allele has a 60-90% lifetime risk of developing breast and a 40-60% risk of developing ovarian cancer (NHS UK). In light of these increased risks predictive genetic testing for BRCA1, BRCA2, TP53 and PTEN mutations are available for those who have a family history of early onset breast cancer.

Bio-Rad offers a variety of antibodies for the analysis of tumor suppressors by ELISA, Flow Cytometry, Immunofluorescence, Immunohistochemistry, Immunoprecipitation and Western Blotting.

Featured products – p53 antibodies

The human p53 protein is a well-studied protein consisting of transactivation (AA 1-94), DNA binding (AA 94-294) and oligomerization/ tetramerization (AA 323-356) domains.

The transactivation domain can be further divided into transactivation domain I (AA 1-43), transactivation domain II (AA 44-63) and a proline-rich region (AA 64-94).

Bio-Rad offers a variety of antibodies for the analysis of the different human p53 domains including:

Clone name Binding region p53 domain Product code
DO-1 AA 20-25 Transactivation MCA1701
BP53-12 AA 20-25 Transactivation OBT3175 
PrecisionAb™ Monoclonal AA 20-25 Transactivation VMA00019K
2C3 AA 94-202 DNA binding and oligomerization MCA3510Z
DO-11 AA 181-190 DNA binding MCA1704
FP3-2 pS392 Oligomerization;
Serine 392 becomes phosphorylated in response to UV damage
MCA1842
Western blot analysis of whole cell lysates probed with anti-p53 antibody

Western blot analysis of whole cell lysates probed with anti-p53 antibody (VMA00019K) followed by detection with HRP conjugated Goat anti Mouse IgG (1/10,000, STAR207P) and visualized on the ChemiDoc MP with 2 second exposure. The arrow points to the p53 protein (molecular weight 53 kDa).

Featured p53 PrecisionAbTM Antibody (VMA00019K)

The anti-p53 antibody (VMA00019K) is part of the PrecisionAb range and has been extensively validated in Western Blotting.

 

PrecisionAb products are characterized by their high specificity, high sensitivity and batch to batch consistency (every lot of antibody meets the same strict quality control criteria).

 

For more information, check our PrecisionAb range.


References

Lodish H et al. (2000). Molecular Cell Biology, 4th edition. New York: W. H. Freeman; 2000.

NHS UK. Predictive gene tests for cancer risk genes. http://www.nhs.uk/conditions/predictive-genetic-tests-cancer/Pages/Introduction.aspx, accessed June 08, 2015.